Armata Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARMP NYSE American 2836 www.armatapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar? - Jul 21st, 2026 5:05 am
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 - Jul 20th, 2026 5:00 am
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia - Jul 13th, 2026 5:00 am
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 - Jun 23rd, 2026 5:00 am
Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy? - Jun 19th, 2026 12:18 pm
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - May 13th, 2026 2:30 pm
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 - May 7th, 2026 5:00 am
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" - May 4th, 2026 5:00 am
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors - Apr 27th, 2026 5:00 am
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results - Mar 25th, 2026 2:05 pm
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update - Mar 19th, 2026 5:00 am
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod - Mar 2nd, 2026 8:23 am
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 - Feb 23rd, 2026 5:00 am
/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./ - Jan 13th, 2026 5:42 am
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST - Nov 18th, 2025 5:00 am
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates - Nov 12th, 2025 3:25 pm
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update - Nov 12th, 2025 2:05 pm
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates - Nov 10th, 2025 6:40 am
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California - Nov 10th, 2025 5:00 am
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates - Nov 6th, 2025 6:15 pm